Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has The Multidrug Resistant Bacteria Market Growth Evolved From 2024 To 2025, And What’s Ahead?

The market size of multidrug resistant bacteria has witnessed robust growth in the recent past. It is projected to escalate from $12.61 billion in 2024 to $13.27 billion in 2025, boasting a compound annual growth rate (CAGR) of 5.2%. Factors contributing to growth in the historic period are the crisis of antibiotic resistance, progress in drug discovery, regulatory stimuli, and initiatives in public health.

In the coming years, the market size for multidrug resistant bacteria is predicted to experience substantial growth, reaching $17.28 billion by 2029 with a compound annual growth rate (CAGR) of 6.8%. The growth throughout the forecast period can be credited to factors such as antibiotic stewardship programs, the worldwide spread of resistance, phage therapy, and alternative treatments, cultivated by both public and private investments. The key trends projected to shape the forecast period are precision medicine for infectious diseases, combination therapies, consistent surveillance and monitoring, as well as global collaboration.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13044&type=smp

How Are Key Drivers in the Industry Acting as Catalysts for the Growth of theMultidrug Resistant Bacteria Market?

The growth of the multidrug-resistant bacteria market is anticipated to be driven by the escalating prevalence of infectious diseases. Harmful microorganisms such as bacteria, viruses, fungi, or parasites are responsible for transmitting these communicable diseases. There’s a strong connection between multidrug-resistant bacteria and infectious diseases as these bacteria have the capability to instigate infections which are challenging to treat with traditional antibiotics. These bacteria have evolved and are now resistant to several antibiotics, rendering the common drugs used to counter bacterial infections less effective. For example, a report by the Centers for Disease Control and Prevention, a US-based national public health organization, in November 2023 specified that tuberculosis cases in the USA have augmented from 8,320 in 2022 to 9,615 in 2023, evidencing an increase of 1,295 cases. Thus, the escalating occurrence of infectious diseases is expected to stimulate the multidrug-resistant bacteria market.

Which Segments in the Multidrug Resistant Bacteria Offer the Most Growth?

The multidrug resistant bacteria market covered in this report is segmented –

1) By Disease: Urinary Tract Infection, Intra-Abdominal Infections, Blood Stream Infections, Clostridium Difficile Infections, Acute Bacterial Skin And Skin Structure Infections, Hospital Acquired Bacterial Pneumonia, Acquired Bacterial Pneumonia, Other Diseases

2) By Drug Class: Oxazolidinones, Lipoglycopeptides, Tetracyclines, Cephalosporins, Combination Therapies, Other Drug Classes

3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

4) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-Users

Subsegments:

1) By Urinary Tract Infection: Cystitis, Pyelonephritis

2) By Intra-Abdominal Infections: Appendicitis, Peritonitis

3) By Blood Stream Infections: Bacteremia, Sepsis

4) By Clostridium Difficile Infections: Mild CDI, Severe CDI

5) By Acute Bacterial Skin And Skin Structure Infections: Cellulitis, Abscesses

6) By Hospital Acquired Bacterial Pneumonia: Ventilator-Associated Pneumonia, Hospital-Acquired Pneumonia

7) By Acquired Bacterial Pneumonia: Community-Acquired Pneumonia, Aspiration Pneumonia

By Other Diseases: Bone and Joint Infections, Endocarditis

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=13044&type=smp

What Are the Fastest-Growing Geographies in the #How Are Key Drivers in the Industry Acting as Catalysts for the Growth of theMultidrug Resistant Bacteria Market?# Market?

North America was the largest region in the multidrug-resistant bacteria market in 2024. The regions covered in multidrug-resistant bacteria market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

What Are the Current Market Growth and Trends in the Multidrug Resistant Bacteria Industry?

Leading firms in the multidrug-resistant bacterial marketplace are honing in on the creation of novel drugs and securing necessary approvals with a view to cater to an emerging customer segment. Gaining approval for drugs targeting multidrug-resistant bacteria is a crucial step in stemming the tide of antibiotic resistance. To illustrate, in May 2023, approval was granted from the US Food and Drug Administration (FDA) to Entasis Therapeutics Inc., a U.S.-based biotech enterprise, for Xacduor, a combined antibiotic that is a proposed treatment for hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VAP) secondary to acinetobacter baumannii. This particular infectious agent can be challenging to successfully treat. The combination treatment comprises ceftolozane, a cephalosporin antibiotic, and tedizolid phosphate, a fresh addition to the oxazolidinone class. The combined treatment offers a fresh route for those patients infected with Acinetobacter baumannii who haven’t seen success with other therapeutic strategies. This novel drug can be administered via injection, merging the antibiotic beta-lactam sulbactam with the broad-spectrum beta-lactamase inhibitor durlobactam. This union decreases acinetobacter resistance, enabling the antibiotic to take effect.

View the full report here:

https://www.thebusinessresearchcompany.com/report/multidrug-resistant-bacteria-global-market-report

What Are the Key Elements That Define the Multidrug Resistant Bacteria Market?

Multidrug-resistant bacteria refer to strains of bacteria that have developed resistance to multiple types or classes of antibiotics. These bacteria are no longer susceptible to the effects of several different antibiotics that would typically be effective in treating bacterial infections. Multidrug-resistant organisms tend to occur in hospitals and medical care facilities when antibiotics are used for longer than necessary or when they are not needed.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13044

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model